GnRH analogs: depot versus short formulations
Gonadotropin releasing hormone agonists (GnRH-a) are widely used in controlled ovarian hyperstimulation (COH) for assisted reproduction (ART). Two different formulations are now available: short formulations and depot formulation. Some authors have suggested that depot GnRH-a induce a too high pitui...
Gespeichert in:
| Veröffentlicht in: | European journal of obstetrics & gynecology and reproductive biology 2004-07, Vol.115, p.S40-S43 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S43 |
|---|---|
| container_issue | |
| container_start_page | S40 |
| container_title | European journal of obstetrics & gynecology and reproductive biology |
| container_volume | 115 |
| creator | Dal Prato, L Borini, A Cattoli, M Bonu, M.A Sereni, E Flamigni, C |
| description | Gonadotropin releasing hormone agonists (GnRH-a) are widely used in controlled ovarian hyperstimulation (COH) for assisted reproduction (ART). Two different formulations are now available: short formulations and depot formulation. Some authors have suggested that depot GnRH-a induce a too high pituitary suppression and have put forward protocols using reduced GnRH-a doses.
A reduced dose of daily triptorelin is enough for pituitary suppression during ovarian stimulation but provides no significant improvement in IVF cycle outcome when compared with depot formulation in normally responding women. However, it seems to improve ovarian response and overall results in poor responding patients.
Low doses of short GnRH-a allow shorter treatment, requiring lower amounts of gonadotropins. This possibility should be considered in view of its economic advantage. |
| doi_str_mv | 10.1016/j.ejogrb.2004.01.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72023684</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030121150400017X</els_id><sourcerecordid>72023684</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-b6a1cdc00bed96a0f5e7eb4908e9146a59688457201189ea2d4e98ea28f6d7493</originalsourceid><addsrcrecordid>eNp9kNFKwzAUhoMobk7fQKQ3eteZ06Zp4oUgQ50wEESvQ5qezpa2mUk78O3N2ECvPPxwbr7_cPgIuQQ6Bwr8tpljY9eumCeUsjmFEHZEpiDyJM55xo7JlKYU4gQgm5Az7xsaJk3lKZlABpLnkE1J_Ny_LSPd69au_V1U4sYO0RadH33kP60bosq6bmz1UNven5OTSrceLw57Rj6eHt8Xy3j1-vyyeFjFJhViiAuuwZSG0gJLyTWtMsyxYJIKlMC4ziQXgmV5QgGERJ2UDKUIW1S8zJlMZ-Rmf3fj7NeIflBd7Q22re7Rjl6FZpJywQLI9qBx1nuHldq4utPuWwFVO02qUXtNaqdJUQjZ1a4O98eiw_K3dPASgOsDoL3RbeV0b2r_h5OQiAwCd7_nMNjY1uiUNzX2BsvaoRlUaev_P_kBjAiGQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72023684</pqid></control><display><type>article</type><title>GnRH analogs: depot versus short formulations</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Dal Prato, L ; Borini, A ; Cattoli, M ; Bonu, M.A ; Sereni, E ; Flamigni, C</creator><creatorcontrib>Dal Prato, L ; Borini, A ; Cattoli, M ; Bonu, M.A ; Sereni, E ; Flamigni, C</creatorcontrib><description>Gonadotropin releasing hormone agonists (GnRH-a) are widely used in controlled ovarian hyperstimulation (COH) for assisted reproduction (ART). Two different formulations are now available: short formulations and depot formulation. Some authors have suggested that depot GnRH-a induce a too high pituitary suppression and have put forward protocols using reduced GnRH-a doses.
A reduced dose of daily triptorelin is enough for pituitary suppression during ovarian stimulation but provides no significant improvement in IVF cycle outcome when compared with depot formulation in normally responding women. However, it seems to improve ovarian response and overall results in poor responding patients.
Low doses of short GnRH-a allow shorter treatment, requiring lower amounts of gonadotropins. This possibility should be considered in view of its economic advantage.</description><identifier>ISSN: 0301-2115</identifier><identifier>EISSN: 1872-7654</identifier><identifier>DOI: 10.1016/j.ejogrb.2004.01.014</identifier><identifier>PMID: 15196715</identifier><identifier>CODEN: EOGRAL</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Biological and medical sciences ; Chemistry, Pharmaceutical ; Delayed-Action Preparations ; Female ; GnRH agonist ; Gonadotropin-Releasing Hormone - agonists ; Gonadotropin-Releasing Hormone - analogs & derivatives ; Gynecology. Andrology. Obstetrics ; Humans ; IVF ; Medical sciences ; Ovarian stimulation ; Ovulation Induction ; Pregnancy ; Reduced dose ; Triptorelin ; Triptorelin Pamoate - administration & dosage</subject><ispartof>European journal of obstetrics & gynecology and reproductive biology, 2004-07, Vol.115, p.S40-S43</ispartof><rights>2004 Elsevier Ireland Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-b6a1cdc00bed96a0f5e7eb4908e9146a59688457201189ea2d4e98ea28f6d7493</citedby><cites>FETCH-LOGICAL-c388t-b6a1cdc00bed96a0f5e7eb4908e9146a59688457201189ea2d4e98ea28f6d7493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejogrb.2004.01.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,777,781,786,787,3537,23911,23912,25121,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15912851$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15196715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dal Prato, L</creatorcontrib><creatorcontrib>Borini, A</creatorcontrib><creatorcontrib>Cattoli, M</creatorcontrib><creatorcontrib>Bonu, M.A</creatorcontrib><creatorcontrib>Sereni, E</creatorcontrib><creatorcontrib>Flamigni, C</creatorcontrib><title>GnRH analogs: depot versus short formulations</title><title>European journal of obstetrics & gynecology and reproductive biology</title><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><description>Gonadotropin releasing hormone agonists (GnRH-a) are widely used in controlled ovarian hyperstimulation (COH) for assisted reproduction (ART). Two different formulations are now available: short formulations and depot formulation. Some authors have suggested that depot GnRH-a induce a too high pituitary suppression and have put forward protocols using reduced GnRH-a doses.
A reduced dose of daily triptorelin is enough for pituitary suppression during ovarian stimulation but provides no significant improvement in IVF cycle outcome when compared with depot formulation in normally responding women. However, it seems to improve ovarian response and overall results in poor responding patients.
Low doses of short GnRH-a allow shorter treatment, requiring lower amounts of gonadotropins. This possibility should be considered in view of its economic advantage.</description><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical</subject><subject>Delayed-Action Preparations</subject><subject>Female</subject><subject>GnRH agonist</subject><subject>Gonadotropin-Releasing Hormone - agonists</subject><subject>Gonadotropin-Releasing Hormone - analogs & derivatives</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>IVF</subject><subject>Medical sciences</subject><subject>Ovarian stimulation</subject><subject>Ovulation Induction</subject><subject>Pregnancy</subject><subject>Reduced dose</subject><subject>Triptorelin</subject><subject>Triptorelin Pamoate - administration & dosage</subject><issn>0301-2115</issn><issn>1872-7654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kNFKwzAUhoMobk7fQKQ3eteZ06Zp4oUgQ50wEESvQ5qezpa2mUk78O3N2ECvPPxwbr7_cPgIuQQ6Bwr8tpljY9eumCeUsjmFEHZEpiDyJM55xo7JlKYU4gQgm5Az7xsaJk3lKZlABpLnkE1J_Ny_LSPd69au_V1U4sYO0RadH33kP60bosq6bmz1UNven5OTSrceLw57Rj6eHt8Xy3j1-vyyeFjFJhViiAuuwZSG0gJLyTWtMsyxYJIKlMC4ziQXgmV5QgGERJ2UDKUIW1S8zJlMZ-Rmf3fj7NeIflBd7Q22re7Rjl6FZpJywQLI9qBx1nuHldq4utPuWwFVO02qUXtNaqdJUQjZ1a4O98eiw_K3dPASgOsDoL3RbeV0b2r_h5OQiAwCd7_nMNjY1uiUNzX2BsvaoRlUaev_P_kBjAiGQQ</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Dal Prato, L</creator><creator>Borini, A</creator><creator>Cattoli, M</creator><creator>Bonu, M.A</creator><creator>Sereni, E</creator><creator>Flamigni, C</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>GnRH analogs: depot versus short formulations</title><author>Dal Prato, L ; Borini, A ; Cattoli, M ; Bonu, M.A ; Sereni, E ; Flamigni, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-b6a1cdc00bed96a0f5e7eb4908e9146a59688457201189ea2d4e98ea28f6d7493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical</topic><topic>Delayed-Action Preparations</topic><topic>Female</topic><topic>GnRH agonist</topic><topic>Gonadotropin-Releasing Hormone - agonists</topic><topic>Gonadotropin-Releasing Hormone - analogs & derivatives</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>IVF</topic><topic>Medical sciences</topic><topic>Ovarian stimulation</topic><topic>Ovulation Induction</topic><topic>Pregnancy</topic><topic>Reduced dose</topic><topic>Triptorelin</topic><topic>Triptorelin Pamoate - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dal Prato, L</creatorcontrib><creatorcontrib>Borini, A</creatorcontrib><creatorcontrib>Cattoli, M</creatorcontrib><creatorcontrib>Bonu, M.A</creatorcontrib><creatorcontrib>Sereni, E</creatorcontrib><creatorcontrib>Flamigni, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dal Prato, L</au><au>Borini, A</au><au>Cattoli, M</au><au>Bonu, M.A</au><au>Sereni, E</au><au>Flamigni, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GnRH analogs: depot versus short formulations</atitle><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>115</volume><spage>S40</spage><epage>S43</epage><pages>S40-S43</pages><issn>0301-2115</issn><eissn>1872-7654</eissn><coden>EOGRAL</coden><abstract>Gonadotropin releasing hormone agonists (GnRH-a) are widely used in controlled ovarian hyperstimulation (COH) for assisted reproduction (ART). Two different formulations are now available: short formulations and depot formulation. Some authors have suggested that depot GnRH-a induce a too high pituitary suppression and have put forward protocols using reduced GnRH-a doses.
A reduced dose of daily triptorelin is enough for pituitary suppression during ovarian stimulation but provides no significant improvement in IVF cycle outcome when compared with depot formulation in normally responding women. However, it seems to improve ovarian response and overall results in poor responding patients.
Low doses of short GnRH-a allow shorter treatment, requiring lower amounts of gonadotropins. This possibility should be considered in view of its economic advantage.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>15196715</pmid><doi>10.1016/j.ejogrb.2004.01.014</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-2115 |
| ispartof | European journal of obstetrics & gynecology and reproductive biology, 2004-07, Vol.115, p.S40-S43 |
| issn | 0301-2115 1872-7654 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72023684 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biological and medical sciences Chemistry, Pharmaceutical Delayed-Action Preparations Female GnRH agonist Gonadotropin-Releasing Hormone - agonists Gonadotropin-Releasing Hormone - analogs & derivatives Gynecology. Andrology. Obstetrics Humans IVF Medical sciences Ovarian stimulation Ovulation Induction Pregnancy Reduced dose Triptorelin Triptorelin Pamoate - administration & dosage |
| title | GnRH analogs: depot versus short formulations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A53%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GnRH%20analogs:%20depot%20versus%20short%20formulations&rft.jtitle=European%20journal%20of%20obstetrics%20&%20gynecology%20and%20reproductive%20biology&rft.au=Dal%20Prato,%20L&rft.date=2004-07-01&rft.volume=115&rft.spage=S40&rft.epage=S43&rft.pages=S40-S43&rft.issn=0301-2115&rft.eissn=1872-7654&rft.coden=EOGRAL&rft_id=info:doi/10.1016/j.ejogrb.2004.01.014&rft_dat=%3Cproquest_cross%3E72023684%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72023684&rft_id=info:pmid/15196715&rft_els_id=S030121150400017X&rfr_iscdi=true |